TY - JOUR T1 - Use of Physician Global Assessment (PGA) in Systemic lupus erythematosus: a systematic review of its psychometric properties JF - medRxiv DO - 10.1101/2020.04.14.20064683 SP - 2020.04.14.20064683 AU - Elisabetta Chessa AU - Matteo Piga AU - Alberto Floris AU - Hervé Devilliers AU - Alberto Cauli AU - Laurent Arnaud Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/17/2020.04.14.20064683.abstract N2 - Background Physician Global Assessment (PGA) is a visual analogue score (VAS) that reflects the clinician’s judgment of overall Systemic Lupus Erythematosus (SLE) disease activity. The aim of this systematic literature review (SLR) is to describe and analyse the psychometric properties of PGA.Methods This SLR was conducted by two independent reviewers in accordance with the PRISMA statement. All articles published until the 1st of July 2019 in Pubmed were screened with no limitation about years of publication, language or patients’ age. Psychometric properties data were analysed according to the OMERACT Filter methodology version 2.1.Results The literature search identified 91 studies. Face validity was reported in all the articles retrieved, in which the PGA was used alone or as part of composite indices (SRI, SFI, LLDAS, DORIS remission criteria). Content validity was reported in 89 studies. Construct validity was demonstrated by a good correlation (r≥0.50) between the PGA with the SLEDAI (12 studies), SLAM (4 studies), LAI, BILAG and ECLAM (2 studies each). Criterion validity was assessed exploring the PGA correlation with quality of life measurements, biomarkers levels and treatment changes in 28 studies, while no study has evaluated correlation with damage. A good responsiveness for PGA was shown in 8 studies. A high variability in scales was found, causing a wide range of reliability (ICC=0.67-0.98).Conclusion PGA is a valid, responsive and feasible instrument, while its reliability was impacted by the scale adopted, suggesting the major need for a standardization of its scoring.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded through the training Bursary Programme 2019 of the SLEuro European Lupus Society (recipient of the bursary: Ms Chessa).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are publicly available in the literature (non proprietary data) ER -